Omeros Stock Falls to 52-Week Low on 1Q Results, Company Pauses Trial

Dow Jones

May 17, 2025

By Kelly Cloonan

Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell.

The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months.

The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share.

The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago.

The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy.

The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 16, 2025 14:32 ET (18:32 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2536927341"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536927341\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536927341?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-17 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536927341","market":"us","top_or_hot":-1,"title":"Omeros Stock Falls to 52-Week Low on 1Q Results, Company Pauses Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell. \n</p>\n<p>\n  The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share. \n</p>\n<p>\n  The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago. \n</p>\n<p>\n  The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy. \n</p>\n<p>\n  The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 14:32 ET (18:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omeros Stock Falls to 52-Week Low on 1Q Results, Company Pauses Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmeros Stock Falls to 52-Week Low on 1Q Results, Company Pauses Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-17 02:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell. \n</p>\n<p>\n  The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months. \n</p>\n<p>\n  The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share. \n</p>\n<p>\n  The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago. \n</p>\n<p>\n  The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy. \n</p>\n<p>\n  The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 16, 2025 14:32 ET (18:32 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMER","symbol_name":"奥麦罗制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2536927341","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536927341","pubTimestamp":1747420320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell.The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months.The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share.The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago.The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy.The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMER":"奥麦罗制药","BK4007":"制药"},"translate_title":"Omeros股价因第一季度业绩跌至52周低点，公司暂停试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMER":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Omeros fell after the company reported lower royalties after sales of its partner Rayner fell. \n\n\n  The stock fell 14% to $3.42 after touching a 52-week low. Shares have risen 3.2% over the past 12 months. \n\n\n  The biopharmaceutical company on Thursday posted a loss of $33.5 million, or 58 cents a share, compared with a loss of $37.2 million, or 63 cents a share, a year earlier. Analysts polled by FactSet expected a loss of 57 cents a share. \n\n\n  The company saw $6.7 million in royalties for its Omidria treatment from Rayner's U.S. sales of $22.3 million, down from royalties of $9.4 million on sales of $31.2 million a year ago. \n\n\n  The company also said it has temporarily paused certain activities to prioritize spending on the launch of narsoplimab, a treatment for transplant-associated thrombotic microangiopathy. \n\n\n  The suspended operations include its Phase 3 trial evaluating zaltenibart, a treatment for paroxysmal nocturnal hemoglobinuria. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 16, 2025 14:32 ET (18:32 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}